Spotlight On
<ѻý class="page-description">— New research focuses on interventions for highest-risk patients
Latest in Spotlight On
Though only one approved agent has been available for decades, the armamentarium has expanded
A major reason for the increase in prevalence is increased survival from improved management
While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group
"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy
While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group
"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy
More in Spotlight On
Delayed diagnosis may affect patients in multiple ways
Molecular heterogeneity, an immunosuppressive microenvironment, less accessible targets
Momentum grows for earlier intervention, including pre-fibrotic disease
The approval of lazertinib/amivantamab gives clinicians one more option
TKIs are the first-line of defense, but "the more options we have the better," expert says
Got COVID from a sick family member? Maybe not, studies show
Use of immune checkpoint inhibitors comes with a variety of potential side effects
We may never have answers to some questions, expert says
It can look like other movement disorders, but there are key differences
Adoptive cell therapy, bispecific antibodies, novel immunotherapies among numerous strategies
Treatment with tocilizumab and steroids is standard, but new therapies are emerging
